Table 2.

Meta-analysis of the relationships of VEGF genetic polymorphisms with the risk of diabetic nephropathy in patients with diabetes mellitus.

	M allele vs. W allele			WM + MM vs. WW			MM vs. WW + WM			MM vs. WW			MM vs. WM
	(Allele model)			(Dominant model)			(Recessive model)			(Homozygous model)			(Heterozygous model)
	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
Overall	1.17	1.05−1.29	0.004	1.20	1.04−1.39	0.010	1.17	1.02−1.34	0.030	1.29	1.06−1.56	0.010	1.12	0.98−1.28	0.103
SNP
rs6921438 Y/X	0.88	0.76−1.04	0.130	0.83	0.65−1.06	0.129	0.88	0.67−1.16	0.366	0.79	0.58−1.09	0.152	0.94	0.70−1.26	0.682
rs10738760 Y/X	1.08	0.93−1.27	0.316	1.13	0.88−1.45	0.339	1.09	0.84−1.41	0.522	1.16	0.85−1.58	0.337	1.05	0.79−1.38	0.751
rs2010963 G/C	1.26	1.05−1.52	0.015	1.29	1.05−1.59	0.015	1.44	1.00−2.05	0.047	1.65	1.08−2.50	0.020	1.28	0.94−1.74	0.115
rs699947 G/A	1.04	0.85−1.29	0.668	0.95	0.69−1.30	0.736	1.22	0.85−1.75	0.288	1.15	0.75−1.76	0.516	1.29	0.86−1.96	0.223
rs3025039 C/T	1.38	1.06−1.80	0.018	1.53	1.02−2.27	0.037	1.39	0.98−1.98	0.062	1.56	1.06−2.30	0.023	1.27	0.87−1.84	0.210
rs833061 C/T	1.17	0.74−1.83	0.502	1.16	0.59−2.29	0.659	1.42	0.57−3.55	0.449	1.50	0.54−4.16	0.431	1.38	0.53−3.56	0.507
2549 D/I	1.12	0.84−1.50	0.442	1.27	0.84−1.92	0.251	0.98	0.57−1.69	0.951	1.13	0.62−2.08	0.684	0.88	0.50−1.56	0.661
Ethnicity
Caucasians	1.03	0.95−1.12	0.449	1.02	0.90−1.16	0.711	1.07	0.93−1.23	0.368	1.07	0.91−1.26	0.421	1.07	0.92−1.24	0.401
Asians	1.36	1.17−1.59	<0.001	1.46	1.19−1.79	<0.001	1.46	1.12−1.91	0.005	1.72	1.27−2.31	<0.001	1.31	0.99−1.74	0.061
Method
Non-PCR-PFLP	1.04	0.94−1.14	0.453	1.00	0.88−1.15	0.944	1.10	0.94−1.28	0.247	1.11	0.90−1.36	0.344	1.10	0.94−1.29	0.232
PCR-RFLP	1.31	1.13−1.52	<0.001	1.44	1.21−1.71	<0.001	1.32	1.03−1.70	0.029	1.57	1.18−2.10	0.002	1.16	0.90−1.51	0.243

W: wild allele; M: mutant allele; WW: wild homozygote; WM: heterozygote; MM: mutant homozygote; OR: odds ratio; 95%CI: 95% confidence interval; SNP: single nucleotide polymorphism.